デフォルト表紙
市場調査レポート
商品コード
1621420

固形臓器移植の拒絶反応市場:提供品目別、臓器タイプ別、拒絶反応タイプ別、エンドユーザー別-2025-2030年の世界予測

Solid Organ Transplantation Rejection Market by Offering (Diagnosis & Testing Solutions, Medications), Organ Type (Heart, Kidneys, Liver), Rejection Type, End-User - Global Forecast 2025-2030


出版日
発行
360iResearch
ページ情報
英文 197 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.66円
固形臓器移植の拒絶反応市場:提供品目別、臓器タイプ別、拒絶反応タイプ別、エンドユーザー別-2025-2030年の世界予測
出版日: 2024年12月01日
発行: 360iResearch
ページ情報: 英文 197 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

固形臓器移植の拒絶反応市場は、2023年に77億9,000万米ドルと評価され、2024年には81億5,000万米ドルに達すると予測され、CAGR 4.90%で成長し、2030年には108億9,000万米ドルに達すると予測されています。

調査手法は、移植臓器の拒絶反応を予防・対処するための医学的進歩の追求によって定義され、免疫抑制薬や検出・治療方法の革新に重点が置かれています。この市場の必要性は、移植臓器の寿命と機能性を向上させ、それによって患者の転帰を改善するという重大な必要性から生じています。最終用途は心臓、腎臓、肝臓、肺、膵臓移植で、用途は主に病院、移植センター、研究機関に及ぶ。市場成長は、臓器移植手術の増加、臓器不全の発生率の上昇、バイオテクノロジーの進歩、高齢者人口の増加などの要因に影響されます。さらに、新規免疫抑制剤や非侵襲的診断技術の開発は、有利な機会をもたらします。研究機関との提携を活用し、個別化医療のアプローチに投資する企業は、市場を大きく牽引できる可能性があります。しかし、市場の拡大は、高額な治療費、既存治療による副作用、規制上の課題、臓器提供者の不足といった限界に直面しています。臓器調達と臓器配分をめぐる倫理的懸念は、成長へのさらなる課題となっています。バイオシミラーや革新的なドラッグデリバリーシステムには、有効性を最大化しながらコスト問題を解決できる可能性があります。拒絶反応のリスクを予測する遺伝子検査、安全な臓器マッチングのためのブロックチェーン、患者モニタリングのためのAIなど、個別化医療のアプローチは有望な研究分野です。市場競争は激しく、新興市場の獲得には戦略的提携と地理的拡大が不可欠です。技術革新を目指す企業にとって、既存の免疫抑制技術と新たな技術を組み合わせたハイブリッド・アプローチは、コストや規制上のハードルを管理しながら、臓器拒絶反応を予防するための強固なソリューションを提供することができます。結局のところ、市場の成長を維持し、複雑化する移植医療に対応するためには、有効性、価格、患者の安全性のバランスを取るための継続的な調査が必要です。

主な市場の統計
基準年[2023] 77億9,000万米ドル
推定年[2024] 81億5,000万米ドル
予測年[2030] 108億9,000万米ドル
CAGR(%) 4.90%

市場力学:急速に進化する固形臓器移植の拒絶反応市場の主要市場インサイトを公開

固形臓器移植の拒絶反応市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

  • 市場促進要因
    • 世界の臓器移植件数の増加
    • 移植と拒絶反応の管理の進歩に対する意識の高まり
  • 市場抑制要因
    • 移植手術に伴う高コスト
  • 市場機会
    • 免疫抑制治療とモニタリング技術の進歩
    • 拒絶反応のリスクを正確に予測するための遺伝子検査の登場
  • 市場の課題
    • 免疫抑制療法に伴う複雑さ

ポーターのファイブフォース:固形臓器移植の拒絶反応市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析:固形臓器移植の拒絶反応市場における外部からの影響の把握

外部マクロ環境要因は、固形臓器移植の拒絶反応市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析固形臓器移植の拒絶反応市場における競合情勢の把握

固形臓器移植の拒絶反応市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス固形臓器移植の拒絶反応市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、固形臓器移植の拒絶反応市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨固形臓器移植の拒絶反応市場における成功への道筋を描く

固形臓器移植の拒絶反応市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています:

1.市場の浸透度:現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度:新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化:最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報:競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション:将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています:

1.現在の市場規模と今後の成長予測は?

2.最高の投資機会を提供する製品、セグメント、地域はどこか?

3.市場を形成する主な技術動向と規制の影響とは?

4.主要ベンダーの市場シェアと競合ポジションは?

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中で臓器移植件数が増加
      • 移植と拒絶反応管理の進歩に関する認識の高まり
    • 抑制要因
      • 移植手術に伴う高額な費用
    • 機会
      • 免疫抑制治療とモニタリング技術の進歩
      • 拒絶反応リスクの予測精度を向上させる遺伝子検査の登場
    • 課題
      • 免疫抑制療法に伴う複雑さ
  • 市場セグメンテーション分析
    • 提供内容:移植臓器の拒絶反応を治療するための薬剤の必要性が高まっている
    • エンドユーザー:病院での管理に広く使用されている固形臓器移植の拒絶反応
  • ポーターのファイブフォース分析
  • PESTEL分析
    • 政治的
    • 経済
    • 社交
    • 技術的
    • 法律上
    • 環境

第6章 固形臓器移植の拒絶反応市場:提供別

  • 診断およびテストソリューション
    • 生検
    • 血液検査
    • 画像検査
  • 医薬品
    • 抗体
    • 代謝拮抗物質
    • カルシニューリン阻害剤
    • ステロイド

第7章 固形臓器移植の拒絶反応市場臓器タイプ別

  • 心臓
  • 腎臓
  • 肝臓
  • 膵臓

第8章 固形臓器移植の拒絶反応市場拒否タイプ別

  • 急性拒絶反応
  • 慢性的な拒絶反応
  • 超急性拒絶反応

第9章 固形臓器移植の拒絶反応市場:エンドユーザー別

  • 病院
  • 専門クリニック

第10章 南北アメリカの固形臓器移植の拒絶反応市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域の固形臓器移植の拒絶反応市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの固形臓器移植の拒絶反応市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
    • 先駆的なパートナーシップが臓器移植拒絶反応予防の画期的進歩を目指す
    • 移植後モニタリングの新開発:リアルタイム電子臓器健康トラッカー
    • GenDx、肺移植モニタリング強化のためトリノ大学からcfDNAアッセイのライセンシングを取得
  • 戦略分析と提言

企業一覧

  • Abbott Laboratories
  • Accord Healthcare Limited
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Biocon
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eris Lifesciences Ltd.
  • Eurofins Transplant Diagnostics
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Globela Pharma
  • Lupin Limited
  • Manus Aktteva Biopharma LLP
  • Natco Pharma Ltd.
  • Novartis AG
  • Panacea Biotec Pharma Ltd.
  • Pfizer Inc.
  • Plexision
  • Sanofi S.A.
  • SAS Alsachim by Shimadzu Group
  • Strides Pharma Global Pte Ltd.
  • Teva Pharmaceuticals Inc.
  • Thermo Fisher Scientific Inc.
  • Veloxis Pharmaceuticals A/S
  • Zydus Lifesciences Limited
図表

LIST OF FIGURES

  • FIGURE 1. SOLID ORGAN TRANSPLANTATION REJECTION MARKET RESEARCH PROCESS
  • FIGURE 2. SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. SOLID ORGAN TRANSPLANTATION REJECTION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. SOLID ORGAN TRANSPLANTATION REJECTION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SOLID ORGAN TRANSPLANTATION REJECTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SOLID ORGAN TRANSPLANTATION REJECTION MARKET DYNAMICS
  • TABLE 7. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HEART, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY KIDNEYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LIVER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LUNGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY PANCREAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ACUTE REJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CHRONIC REJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HYPERACUTE REJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 282. SOLID ORGAN TRANSPLANTATION REJECTION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 283. SOLID ORGAN TRANSPLANTATION REJECTION MARKET, FPNV POSITIONING MATRIX, 2023
目次
Product Code: MRR-CB04E05661AD

The Solid Organ Transplantation Rejection Market was valued at USD 7.79 billion in 2023, expected to reach USD 8.15 billion in 2024, and is projected to grow at a CAGR of 4.90%, to USD 10.89 billion by 2030.

The market for solid organ transplantation rejection therapies is defined by the pursuit of medical advancements to prevent and address the rejection of transplanted organs, focusing on immunosuppressive drugs and innovations in detection and treatment methodologies. The necessity of this market arises from the critical need to enhance the longevity and functionality of transplanted organs, thereby improving patient outcomes. Application primarily spans hospitals, transplant centers, and research institutions, with end-use targeting heart, kidney, liver, lung, and pancreas transplants. Market growth is influenced by factors such as increasing organ transplant procedures, rising incidences of organ failure, advancements in biotechnology, and a growing elderly population. Moreover, the development of novel immunosuppressants and non-invasive diagnostic techniques presents lucrative opportunities. Companies that leverage partnerships with research institutions and invest in personalized medicine approaches can potentially gain substantial market traction. However, market expansion faces limitations such as high treatment costs, side effects from existing therapies, regulatory challenges, and a lack of organ donors. Ethical concerns surrounding organ sourcing and allocation further challenge growth. Opportunities lie in biosimilars and innovative drug delivery systems, which could address cost issues while maximizing efficacy. Personalized medicine approaches, including genetic testing to predict rejection risk, blockchain for secure organ matching, and AI for patient monitoring, represent promising research areas. As the market is highly competitive, strategic collaborations and geographic expansion are essential for capturing emerging markets. For companies looking to innovate, hybrid approaches that combine existing immunosuppressive techniques with emerging technologies can offer robust solutions for preventing organ rejection while managing cost and regulatory hurdles. Ultimately, the market requires continuous research into balancing efficacy, affordability, and patient safety to sustain growth and meet the increasing complexity of transplantation medicine.

KEY MARKET STATISTICS
Base Year [2023] USD 7.79 billion
Estimated Year [2024] USD 8.15 billion
Forecast Year [2030] USD 10.89 billion
CAGR (%) 4.90%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Solid Organ Transplantation Rejection Market

The Solid Organ Transplantation Rejection Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing number of organ transplants worldwide
    • Rising awareness about the advancements in transplantation and rejection management
  • Market Restraints
    • High costs associated with transplantation procedures
  • Market Opportunities
    • Advancements in immunosuppressive treatments and monitoring technologies
    • Emergence of genetic testing to improve predicting rejection risks accurately
  • Market Challenges
    • Complexities associated with immunosuppressive therapies

Porter's Five Forces: A Strategic Tool for Navigating the Solid Organ Transplantation Rejection Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Solid Organ Transplantation Rejection Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Solid Organ Transplantation Rejection Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Solid Organ Transplantation Rejection Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Solid Organ Transplantation Rejection Market

A detailed market share analysis in the Solid Organ Transplantation Rejection Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Solid Organ Transplantation Rejection Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Solid Organ Transplantation Rejection Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Solid Organ Transplantation Rejection Market

A strategic analysis of the Solid Organ Transplantation Rejection Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Solid Organ Transplantation Rejection Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accord Healthcare Limited, Asahi Kasei Corporation, Astellas Pharma Inc., Biocon, Cipla Ltd., Dr. Reddy's Laboratories Ltd., Eris Lifesciences Ltd., Eurofins Transplant Diagnostics, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Globela Pharma, Lupin Limited, Manus Aktteva Biopharma LLP, Natco Pharma Ltd., Novartis AG, Panacea Biotec Pharma Ltd., Pfizer Inc., Plexision, Sanofi S.A., SAS Alsachim by Shimadzu Group, Strides Pharma Global Pte Ltd., Teva Pharmaceuticals Inc., Thermo Fisher Scientific Inc., Veloxis Pharmaceuticals A/S, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Solid Organ Transplantation Rejection Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Offering, market is studied across Diagnosis & Testing Solutions and Medications. The Diagnosis & Testing Solutions is further studied across Biopsy, Blood Tests, and Imaging Tests. The Medications is further studied across Antibodies, Antimetabolites, Calcineurin Inhibitors, and Steroids.
  • Based on Organ Type, market is studied across Heart, Kidneys, Liver, Lungs, and Pancreas.
  • Based on Rejection Type, market is studied across Acute Rejection, Chronic Rejection, and Hyperacute Rejection.
  • Based on End-User, market is studied across Hospitals and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing number of organ transplants worldwide
      • 5.1.1.2. Rising awareness about the advancements in transplantation and rejection management
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with transplantation procedures
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in immunosuppressive treatments and monitoring technologies
      • 5.1.3.2. Emergence of genetic testing to improve predicting rejection risks accurately
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities associated with immunosuppressive therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Increasing need for medication to treat the rejection of the transplanted organ
    • 5.2.2. End-User: Extensive use in hospitals for managing solid organ transplantation rejection
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Solid Organ Transplantation Rejection Market, by Offering

  • 6.1. Introduction
  • 6.2. Diagnosis & Testing Solutions
    • 6.2.1. Biopsy
    • 6.2.2. Blood Tests
    • 6.2.3. Imaging Tests
  • 6.3. Medications
    • 6.3.1. Antibodies
    • 6.3.2. Antimetabolites
    • 6.3.3. Calcineurin Inhibitors
    • 6.3.4. Steroids

7. Solid Organ Transplantation Rejection Market, by Organ Type

  • 7.1. Introduction
  • 7.2. Heart
  • 7.3. Kidneys
  • 7.4. Liver
  • 7.5. Lungs
  • 7.6. Pancreas

8. Solid Organ Transplantation Rejection Market, by Rejection Type

  • 8.1. Introduction
  • 8.2. Acute Rejection
  • 8.3. Chronic Rejection
  • 8.4. Hyperacute Rejection

9. Solid Organ Transplantation Rejection Market, by End-User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Specialty Clinics

10. Americas Solid Organ Transplantation Rejection Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Solid Organ Transplantation Rejection Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Solid Organ Transplantation Rejection Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Pioneering Partnership Targets Breakthrough in Organ Transplant Rejection Prevention
    • 13.3.2. New Development in Post-Transplant Monitoring: Real-Time Electronic Organ Health Tracker
    • 13.3.3. GenDx Acquires Licensing for cfDNA Assay from Torino University to Enhance Lung Transplant Monitoring
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Accord Healthcare Limited
  • 3. Asahi Kasei Corporation
  • 4. Astellas Pharma Inc.
  • 5. Biocon
  • 6. Cipla Ltd.
  • 7. Dr. Reddy's Laboratories Ltd.
  • 8. Eris Lifesciences Ltd.
  • 9. Eurofins Transplant Diagnostics
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. GlaxoSmithKline PLC
  • 12. Globela Pharma
  • 13. Lupin Limited
  • 14. Manus Aktteva Biopharma LLP
  • 15. Natco Pharma Ltd.
  • 16. Novartis AG
  • 17. Panacea Biotec Pharma Ltd.
  • 18. Pfizer Inc.
  • 19. Plexision
  • 20. Sanofi S.A.
  • 21. SAS Alsachim by Shimadzu Group
  • 22. Strides Pharma Global Pte Ltd.
  • 23. Teva Pharmaceuticals Inc.
  • 24. Thermo Fisher Scientific Inc.
  • 25. Veloxis Pharmaceuticals A/S
  • 26. Zydus Lifesciences Limited